299 related articles for article (PubMed ID: 12435293)
1. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
Davidson NE
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
[TBL] [Abstract][Full Text] [Related]
2. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel in the treatment of breast cancer: an update on recent studies.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
5. The European experience with docetaxel in the treatment of early-stage breast cancer.
Di Leo A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S59-62. PubMed ID: 12435289
[TBL] [Abstract][Full Text] [Related]
6. The role of taxanes in the adjuvant treatment of early stage breast cancer.
Piccart M
Breast Cancer Res Treat; 2003; 79 Suppl 1():S25-34. PubMed ID: 12868803
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
8. The expanding role of epirubicin in the treatment of breast cancer.
Glück S
Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
[TBL] [Abstract][Full Text] [Related]
9. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
10. [Role of taxanes in treatment of breast cancer].
Gorbunova VA; Besova NS
Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
[No Abstract] [Full Text] [Related]
11. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
12. Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Heinemann V
Oncology; 2003; 64(3):191-206. PubMed ID: 12697958
[TBL] [Abstract][Full Text] [Related]
13. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
14. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
Nabholtz JM; Riva A
Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
[TBL] [Abstract][Full Text] [Related]
15. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
16. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
Valero V; Hortobagyi GN
J Clin Oncol; 2003 Mar; 21(6):959-62. PubMed ID: 12637456
[No Abstract] [Full Text] [Related]
17. Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab.
Smith I
Ann Oncol; 2001; 12 Suppl 1():S75-9. PubMed ID: 11521726
[TBL] [Abstract][Full Text] [Related]
18. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
